Research presented at the annual meeting of the Academy of Managed Care Pharmacy — AMCP Nexus 2019 — highlighted real-world treatment patterns and costs for patients with schizophrenia and bipolar disorder in the United States.

According to researchers, second-generation antipsychotics (SGAs) have become common treatment options for both schizophrenia and bipolar disorders, but associated costs and actual treatment patterns in the U.S. for both disorders have not been comprehensively reviewed.